Accessibility StatementSkip Navigation – Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelcaand atezolizumab (Tecentriq) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex, Xywavand the launch of Modeyso – DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial g ...

Revenues up 100% year-over-year to a record $1.27 billionNet Deposits were a record $20 billion, and Robinhood Gold Subscribers reached a record 3.9 millionDiluted EPS up 259% year-over-year to $0.61Robinhood now up to 11 business lines each generating ~$100 million or more in annualized revenues MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the third quarter of 2025, which ended September 30, 2025. "Our team’ ...

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Total revenue for the third quarter of 2025 was $52.3 million, representing a 2% increase compared to the third quarter of 2024Expanded to a total installed base of 3,456 Cytek instruments, adding 161 units in the third quarter of 2025Double-dig ...

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income(2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 2026 Positive, Statistically Significant Real-World Health Outcomes Demonstrated for ASCENIV™ Record ASCENIV Demand a ...

ANDOVER, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced that it is experiencing traction with houses of worship and schools as growing national attention shifts towards less-lethal protection options. Byrna’s mission to provide an effective means of defense without resorting to deadly f ...

JOHANNESBURG, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the first quarter of fiscal 2026 (“Q1 2026”). Q1 2026 performance1:All growth rates are year-on-year between Q1 FY2026 and Q1 FY2025. Revenue of $171.5 million (ZAR 3.0 billion) up 10% in ZAR.Net Revenue2 of $86.6 million (ZAR 1.5 billion), up 45% in ZAR.Operating Income of $0.4 million (ZAR 6.7 million), improved from a loss of $0.1 million (ZAR 0.3 million).Net Loss of $4.3 million ...

DELAWARE, Ohio, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Greif, Inc. (NYSE: GEF, GEF.B), a world leader in industrial packaging products and services, today announced two-month fourth quarter and eleven-month fiscal 2025 results. On June 30, 2025, we entered into a definitive agreement to divest our containerboard business, including our CorrChoice sheet feeder system (the “Containerboard Business”), in an all-cash transaction for $1.8 billion to Packaging Corporation of America. The transaction closed as of Augus ...

BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third quarter 2025 financial results. “We have made significant progress advancing our promising ADC programs,” said Michael Richman, NextCure’s president and CEO. “We recently began U.S. enrollment in the Phase 1 trial for SIM0505, ...

Third quarter revenue grew 20% to $74.0 million; Gross margin improved to 32.0% Net income grew 59% to $12.4 million or $0.27 per diluted shareSubstantial cash position and no debt at September 30, 2025 WOODCLIFF LAKE, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Hudson Technologies, Inc. (NASDAQ: HDSN) announced results for the third quarter and nine months ended September 30, 2025. Brian Bertaux, Chief Financial Officer of Hudson Technologies commented, “Hudson achieved strong third quarter results to close ou ...

- Reflecting Improvement in All Segments, Gross Profit of $23 Million Increased $18 Million, Net Income of $14 Million, or $0.19 per Share, Improved $17 Million and Adj. EBITDA of $21 Million Grew $9 Million Compared to Q3 2024 -PEKIN, Ill., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter ended September 30, 2025. “Our 2025 initiatives t ...